Intelligent Bio Solutions (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25
The company's non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates.
Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings.
INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity.
The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety.
INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery.
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies (https://ibn.fm/1JSTS).
The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for…
Read More>>
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
Is Fortinet's FortiGuard AI Service Becoming a Key Growth Driver?
Fortinet 's FTNT FortiGuard AI-powered security services have been gaining traction as more enterprises turn to real-time, automated protection to secure users, data and infrastructure. These services, which include threat intelligence, intrusion prevention, data loss prevention (DLP), antivirus and web filtering, are powered by FortiGuard Labs' global sensor network and AI models. Strong adoption has been driving top-line growth. In the first quarter of fiscal 2025, service revenues of $1.08 billion increased 14% year over year. Security subscriptions, including FortiGuard services, grew 16% year over year and remain a key driver of service growth. It made up 57.7% of Fortinet's service revenues in the first quarter. Services now make up more than 70% of Fortinet's total revenues, underscoring the importance of recurring, AI-powered solutions in its business model. Fortinet's continued focus on expanding FortiGuard's reach is visible in the launch of its AI-powered Workspace Security Suite. The suite protects key productivity platforms like Microsoft 365 and Google Workspace with AI-based phishing detection, impersonation defense, DLP and 24/7 incident response. These capabilities are fully backed by FortiGuard's intelligence and seamlessly integrate into Fortinet's broader Security Fabric to automate threat response and improve detection accuracy. Fortinet's AI services are a long-term growth driver. The company is deepening AI integration across its service portfolio and holds more than 500 AI-related patents. As demand grows for scalable, intelligence-led protection across hybrid and cloud environments, Fortinet expects its AI-enhanced services, such as FortiGuard, to contribute meaningfully to recurring, high-margin revenue growth. FTNT Faces Stiff Competition Fortinet's FortiGuard AI-powered services face growing competition from Palo Alto Networks PANW and Cisco Systems CSCO, both of which are expanding their AI security capabilities. Palo Alto Networks is expanding its AI security footprint with the acquisition of Protect AI, a leader in securing AI and ML applications. The move strengthens Palo Alto Networks' capabilities to defend against emerging threats like model manipulation and prompt injection. It reflects the company's push to lead in next-generation cybersecurity by addressing risks in the growing AI ecosystem. Meanwhile, Cisco Systems is boosting its AI security capabilities with updates to its XDR and Splunk platforms. It introduced agentic AI for faster threat detection and launched Foundation AI, featuring the first reasoning model for security. Cisco Systems also expanded its partnership with ServiceNow to support secure, scalable AI adoption. FTNT's Share Price Performance, Valuation and Estimates FTNT shares have risen 9.8% in the year-to-date (YTD) period, underperforming the Zacks Security industry's growth of 21.9%. FTNT has outperformed the Zacks Computer and Technology sector's return of 1.3%. FTNT's YTD Price Performance From a valuation standpoint, Fortinet stock is currently trading at a Price/Book ratio of 40.88X compared with the industry's 24.58X. FTNT has a Value Score of F. FTNT Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at 59 cents per share, unchanged over the past 30 days, indicating 3.51% year-over-year growth. The consensus mark for 2025 earnings is pegged at $2.48 per share, which has been revised upward by 2 cents over the past 30 days. The estimate indicates 4.64% year-over-year growth. Fortinet currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report Fortinet, Inc. (FTNT): Free Stock Analysis Report Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report
National Post
30 minutes ago
- National Post
Elbows-up tourism surge could see sector ‘eke out' a gain even as Americans stay away
From the front desk of Hotel Bedford in Goderich, Ont., Lynda Cross welcomes guests from regions ranging from southern Ontario to the South Pacific. Article content 'A lot of them come from Toronto,' said the manager, standing just inside the Romanesque arches of the 129-year-old establishment. 'Just lately, we've had a few groups come from Australia' — a first, she said. Article content Article content But one crop of tourists has been conspicuously absent this year: Americans. Article content Article content 'May and June have been slow.' Article content Article content A groundswell of economic patriotism has stoked curiosity in Canadian destinations, fuelling a domestic bookings surge as travellers turn away from cross-border trips. But a drop in American visitors north of the border and fears that many Canadians will simply stay home to save money has many wondering whether homegrown and overseas tourism can make up for the stateside decline. Article content Canadian vacationers' boycotting the U.S. could net this country's tourism sector up to $8.8 billion in extra business this year as travellers explore spots closer to home, according to a report from the Conference Board of Canada. Article content An April survey on travel intentions prompted the group to predict a windfall despite fewer border crossings this year by American tourists — Canada's largest source of inbound travellers by far. Article content The number of Americans who visited Canada by car fell nearly 11 per cent in April compared with the same month last year, the third straight month of year-over-year decreases, according to Statistics Canada. Article content While trip numbers for Canadians heading to the U.S. have fallen off far more steeply as part of a backlash against U.S. President Donald Trump's tariffs and '51st state' threats, Americans' more moderate pullback owes to factors ranging from pinched pocketbooks to fears of feeling unwelcome to angst over the border crossing on the drive home. Article content The American retreat could hit communities that hug the border especially hard. Article content Article content 'Border towns that have tended to experience the shorter, more frequent back-and-forth visits — those are going to be communities that are going to be more heavily affected,' said Andrew Siegwart, who heads the Tourism Industry Association of Ontario.
Globe and Mail
35 minutes ago
- Globe and Mail
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas. Quick Take on Recent Acquisitions & Deals Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology. The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio. Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed. Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. M&A in Focus in 2025 Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky. In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio. Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree. Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. Potential Deals We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies. These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
